KR20060127931A - 피페라실린 및 타조박탐을 포함하고 실질적으로갈락토만난을 포함하지 않는 조성물 - Google Patents

피페라실린 및 타조박탐을 포함하고 실질적으로갈락토만난을 포함하지 않는 조성물 Download PDF

Info

Publication number
KR20060127931A
KR20060127931A KR1020067015252A KR20067015252A KR20060127931A KR 20060127931 A KR20060127931 A KR 20060127931A KR 1020067015252 A KR1020067015252 A KR 1020067015252A KR 20067015252 A KR20067015252 A KR 20067015252A KR 20060127931 A KR20060127931 A KR 20060127931A
Authority
KR
South Korea
Prior art keywords
piperacillin
pharmaceutical composition
tazobactam
galactomannan
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020067015252A
Other languages
English (en)
Korean (ko)
Inventor
마크 에드워드 루펜
유-펜 왕
샘 매타칼 조지
Original Assignee
와이어쓰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 filed Critical 와이어쓰
Publication of KR20060127931A publication Critical patent/KR20060127931A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020067015252A 2004-01-30 2005-01-27 피페라실린 및 타조박탐을 포함하고 실질적으로갈락토만난을 포함하지 않는 조성물 Withdrawn KR20060127931A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54091004P 2004-01-30 2004-01-30
US60/540,910 2004-01-30

Publications (1)

Publication Number Publication Date
KR20060127931A true KR20060127931A (ko) 2006-12-13

Family

ID=34837439

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067015252A Withdrawn KR20060127931A (ko) 2004-01-30 2005-01-27 피페라실린 및 타조박탐을 포함하고 실질적으로갈락토만난을 포함하지 않는 조성물

Country Status (7)

Country Link
US (1) US20050171077A1 (cg-RX-API-DMAC7.html)
EP (1) EP1711178A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007519747A (cg-RX-API-DMAC7.html)
KR (1) KR20060127931A (cg-RX-API-DMAC7.html)
CN (1) CN1913890A (cg-RX-API-DMAC7.html)
CA (1) CA2553038A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005074925A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1787641A1 (de) * 2005-11-22 2007-05-23 Helm AG Tazobactam-Piperacillin-Lyophilisat
ATE485043T1 (de) * 2005-12-05 2010-11-15 Sandoz Ag Verfahren zur herstellung von lyophilisiertem piperacillin-natrium in kombination mit tazobactam-natrium, mit verbesserter stabilität nach der rekonstitution
ITMI20070568A1 (it) * 2007-03-22 2008-09-23 Acs Dobfar Spa Comosizione farmaceutica sterile iniettabile avente piperacillina sodica e tazobactam sodico come principi attivi
WO2013036783A2 (en) 2011-09-09 2013-03-14 Cubist Pharmaceuticals, Inc. Methods for treating intrapulmonary infections
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
CN103006676B (zh) * 2012-12-27 2015-02-25 石药集团中诺药业(石家庄)有限公司 新型哌拉西林他唑巴坦组合物
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
KR102329764B1 (ko) 2013-03-15 2021-11-23 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CN113209030B (zh) * 2021-04-27 2023-04-25 海南通用康力制药有限公司 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534977A (en) * 1981-03-26 1985-08-13 American Cyanamid Company Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin
US4477452A (en) * 1981-03-26 1984-10-16 American Cyanamid Company Composition of matter comprising a lyophilized preparation of a penicillin derivative
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
AUPQ137699A0 (en) * 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
AU2003230899A1 (en) * 2003-04-14 2004-11-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection

Also Published As

Publication number Publication date
EP1711178A1 (en) 2006-10-18
JP2007519747A (ja) 2007-07-19
CA2553038A1 (en) 2005-08-18
CN1913890A (zh) 2007-02-14
US20050171077A1 (en) 2005-08-04
WO2005074925A8 (en) 2005-12-08
WO2005074925A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
KR100940173B1 (ko) 복막투석액 내의 미생물 오염물질을 검출하기 위한 방법 및조성물
Ramphal et al. The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum
EP1942868B1 (en) Sodium chloride solution for drug reconstitution or dilution
HK1245090A1 (en) Sodium chloride solution for drug reconstitution
HRP20010901A2 (en) Compositions of a-beta peptide and processes for producing same
US20050171077A1 (en) Compositions containing piperacillin and tazobactam
CN105085570B (zh) 一种磷酸特地唑胺化合物及其制备方法
CN115372497B (zh) 一种小活络丸中6种生物碱成分的含量测定方法
KR20250006907A (ko) 조직 칼리크레인 1의 투약 형태
CN100579511C (zh) 一种高纯度氨甲环酸注射剂的获得及其质量标准
NAKAGAWA et al. High speed liquid chromatographic determination of cephalexin in human plasma and urine
US20160193176A1 (en) Chlorogenic acid powder-injection and preparation method thereof
Li et al. Determination of free and total piperacillin–tazobactam in plasma by HPLC–MS–MS: an adapted method for neonates
CN103860483A (zh) 复方甘草酸苷类冻干粉针注射剂及其制备方法
Raghow et al. High-performance liquid chromatographic assay of tolbutamide and carboxytolbutamide in human plasma
CN102846704A (zh) 一种益母草注射液、其制备方法和总生物碱的检测方法
MXPA06008605A (en) Compositions substantially free of galactomannan containing piperacillin and tazobactam
Zimmerli et al. Pharmacokinetics of cefetamet in plasma and skin blister fluid
CN106404953B (zh) 一种青霉素皮试冻干粉剂的质量检测方法
JP2023082167A (ja) 薬物動態及び/又は安全性に優れるテリパラチド含有液状医薬組成物
EP3448377A1 (en) Methods for the treatment of infection
Stoeckel et al. Penetration of cefetamet pivoxil and cefuroxime axetil into the maxillary sinus mucosa at steady state
Kondo et al. Effect of High Blood Glucose Level on the Antimicrobial Activity of Daptomycin against Staphylococcus aureus in Streptozotocin-Induced Diabetic Mice
JP2519954B2 (ja) 診断用負荷試験剤
JP2025533271A (ja) プリナブリンミセル組成物及びその調製方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060728

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid